Financial Performance - The company's operating revenue for Q3 2025 was ¥1,132,883,729.40, representing a year-on-year increase of 0.13%[5] - The net profit attributable to shareholders for Q3 2025 was ¥151,682,862.05, a decrease of 2.37% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥145,557,749.72, showing a slight increase of 0.20% year-on-year[5] - Total operating revenue for the current period reached ¥3,271,797,099.40, an increase of 2.8% compared to ¥3,181,879,566.30 in the previous period[19] - Net profit for the current period was ¥456,066,099.99, compared to ¥442,334,462.70 in the previous period, indicating a growth of 3.1%[20] Assets and Liabilities - The total assets as of September 30, 2025, amounted to ¥8,163,130,801.02, reflecting a growth of 3.02% from the end of the previous year[5] - The company's total assets increased to ¥8,163,130,801.02 from ¥7,924,043,231.64, representing a growth of 3.0%[17] - Total liabilities rose to ¥1,954,785,761.96, up from ¥1,900,587,269.74, marking an increase of 2.8%[17] - The company's equity attributable to shareholders increased to ¥5,998,641,817.34 from ¥5,794,409,772.57, reflecting a growth of 3.5%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥698,110,689.68, an increase of 3.61%[5] - Net cash flow from operating activities was CNY 698,110,689.68, up from CNY 673,755,479.24 in the previous period[23] - Cash inflow from operating activities totaled CNY 3,331,087,546.30, slightly higher than CNY 3,314,706,537.36 last year[22] - Cash outflow from investing activities was CNY 9,327,290,666.34, compared to CNY 7,464,214,439.71 in the previous period, resulting in a net cash flow from investing activities of -CNY 2,866,790,736.89[23] - The company experienced a net cash outflow from financing activities of -CNY 391,334,969.96, an improvement from -CNY 439,006,413.53 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,229[12] - The largest shareholder, Huaxia Medical Investment (Xiamen), holds 30.45% of shares, totaling 255,764,011 shares[12] - The second-largest shareholder, Su Qingcan, holds 30.41% of shares, totaling 255,405,989 shares[12] - The company has a total of 470,247,758 shares controlled by Su Qingcan and related parties, representing 63.00% of total shares[12] - The company has not disclosed any other shareholders with related party relationships or acting in concert[12] Expenses and Income - The company's financial expenses increased by 33.20% year-on-year, primarily due to the use of temporarily idle funds for financial products, resulting in reduced bank interest income[10] - The company reported a significant increase of 671.22% in trading financial assets, totaling ¥2,960,920,870.16, attributed to cash management strategies[10] - The asset disposal income increased by 521.00% year-on-year, mainly due to gains from the disposal of right-of-use assets[10] - The company experienced a 42.77% decrease in non-operating expenses, primarily due to reduced charitable donations[10] - Research and development expenses for the current period were ¥46,537,186.58, down from ¥53,903,578.99, a decrease of 13.7%[20] - The company reported an investment income of ¥31,396,054.12, compared to ¥45,033,384.18 in the previous period, showing a decline of 30.4%[20] Dividends - The company distributed a cash dividend of RMB 2.20 per 10 shares, totaling RMB 183,143,875.20 for the 2024 profit distribution[13] Cash and Cash Equivalents - The cash and cash equivalents decreased from RMB 3,487,699,580.40 to RMB 915,034,696.29[15] - The cash and cash equivalents increased to ¥323,526,661.10 from ¥240,471,990.33, a rise of 34.5%[17] - Cash and cash equivalents at the end of the period stood at CNY 909,526,296.29, down from CNY 1,084,478,851.40[23] Other Financial Metrics - The weighted average return on equity for the reporting period was 2.56%, a decrease of 0.15% compared to the same period last year[5] - Total comprehensive income for the period reached CNY 455,441,542.57, an increase from CNY 442,438,879.20 in the previous period[21] - Basic and diluted earnings per share increased to CNY 0.52 from CNY 0.50[21] - The financial report for the third quarter was not audited[25]
华厦眼科(301267) - 2025 Q3 - 季度财报